search
Back to results

Functional Assessment by Virtual Online Reconstruction. The FAVOR III Europe Japan Study (FAVOR III EJ)

Primary Purpose

Coronary Artery Disease

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
QFR-based diagnostic strategy
FFR-based diagnostic strategy
Sponsored by
Aarhus University Hospital Skejby
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Coronary Artery Disease focused on measuring Fractional Flow Reserve (FFR), Quantitative Flow Ratio (QFR), Stable coronary artery disease, Angina pectoris, Angiography derived fractional flow reserve

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age of 18 years and above
  • Both genders
  • Indication for invasive coronary angiography
  • Patients with stable angina pectoris, or assessment of secondary lesions in stabilized non-STEMI patients or assessment of secondary lesions in patients with prior STEMI and staged evaluation of secondary lesions.
  • Able to provide written informed consent

Angiographic inclusion criteria

  • Diameter stenosis of 40-90% diameter stenosis
  • Vessel diameter of at least 2.5 mm and supplying viable myocardium
  • Patients with restenosis in a native coronary artery can be included

Exclusion Criteria:

  • Severely impaired renal function: Glomerular filtration rate (GFR) < 20 mL/min/1.73m²
  • Life expectancy less than one year
  • Cardiogenic shock or unstable haemodynamic state (Killip class III and IV)
  • ST-elevation myocardial infarction (STEMI) within 72 hours
  • Bypass graft to any target vessel
  • Atrial fibrillation at the time of the procedure
  • Chronic total occlusions of any vessel with possible or established indication for treatment
  • Pregnancy or intention to become pregnant during the course of the trial
  • Breast feeding
  • Planned need for concomitant valvular or aortic surgery
  • Left ventricular ejection fraction (LVEF) < 30%
  • Previous inclusion in the FAVOR III trial
  • Enrolled in another clinical study, and for this reason not treated according to present European Society of Cardiology guidelines, or the protocol treatment conflicts with the protocol treatment of FAVOR III
  • Inability to tolerate contrast media
  • Inability to tolerate Adenosine

Angiographic exclusion criteria

  • Ostial right coronary artery > 50% diameter stenosis
  • Left main coronary artery > 50% diameter stenosis
  • Lesions properties indicative of myocardial bridging
  • Bifurcation lesions with major (>1 mm) step down in reference size across the bifurcation
  • Severe tortuosity of any target vessel
  • Severe overlap in the stenosed segment
  • Poor image quality precluding identification of vessel contours

Sites / Locations

  • Aalborg University Hospital
  • Aarhus University Hospital
  • Gentofte Hospital
  • Institut Arnault Tzanck
  • GCS ES Axium - Parc Rambot
  • CHU de Lille, Lille University Hospital
  • Institut Cardiovasculaire Paris Sud (ICPS), Hopital Jacques Cartier
  • Hopital Haut-Leveque, Pessac
  • Hôpital Privé Claude Galien
  • Clinique Pasteur, Toulouse
  • Charite-Universitatsmedizin Berlin
  • Elisabeth Krankenhaus
  • University Clinic Leipzig
  • Ospedale Maggiore, AUSL Bologna
  • Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara
  • Azienda Ospedaliero Universitaria Federico II di Napoli
  • San Luigi Gonzaga University Hospital, Turin
  • Arcispedale S. Maria Nuova di Reggio Emilia
  • Ospedale degli Infermi di Rimini
  • Ospedale di Rivoli, Torino
  • Azienda Ospedaliera Universitaria integrata Verona
  • Riga Stradini University Hospital
  • Hospital of Lithuanian University of Health Sciences Kauno Klinikos
  • VU University Medical Center
  • Academic Medical Center (AMC)
  • HagaZiekenhuis
  • Medical University of Warsaw
  • Hospital Clinico Universitario Virgen de la Arrixaca
  • Hospital Clinico de Coruña
  • Hospital Lucus Agusti LUGO
  • Hospital Clinico San Carlos
  • Hospital Clinico Universitario de Valladolid
  • Hospital Álvaro Cunqueiro
  • Sahlgrenska University Hospital
  • Barbera Stähli

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

QFR-based diagnostic strategy

FFR-based diagnostic strategy

Arm Description

Intermediate stenosis with indication for evaluation are diagnosed by Quantitative flow ratio (QFR). Revascularization is indicated if QFR≤0.80. Treatment is performed according to standard clinical practice.

Intermediate stenosis with indication for evaluation are diagnosed by fractional flow reserve (FFR). Revascularization is indicated if FFR≤0.80. Treatment is performed according to standard clinical practice.

Outcomes

Primary Outcome Measures

Patient oriented composite endpoint (PoCE)
A composite endpoint of 1) all-cause mortality, 2) any myocardial infarction, and 3) any unplanned revascularization

Secondary Outcome Measures

Target vessel failure
A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization.
Target vessel failure
A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization.
Target vessel failure
A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization.
All-cause mortality
Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons.
All-cause mortality
Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons.
All-cause mortality
Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons.
Cardiac death
Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death
Cardiac death
Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death
Cardiac death
Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death
Myocardial infarction
Procedure and non-procedure related myocardial infarction. Protocol defined.
Myocardial infarction
Procedure and non-procedure related myocardial infarction. Protocol defined.
Myocardial infarction
Procedure and non-procedure related myocardial infarction. Protocol defined.
Target vessel myocardial infarction
As "any myocardial infarction", but with culprit lesion in index vessel.
Target vessel myocardial infarction
As "any myocardial infarction", but with culprit lesion in index vessel.
Target vessel myocardial infarction
As "any myocardial infarction", but with culprit lesion in index vessel.
Any unplanned revascularization
Coronary artery bypass grafting (CABG) or PCI of any lesion. Planned Revascularization: Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated. Unplanned Revascularization: Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
Any unplanned revascularization
Coronary artery bypass grafting (CABG) or PCI of any lesion. Planned Revascularization: Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated. Unplanned Revascularization: Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
Any unplanned revascularization
Coronary artery bypass grafting (CABG) or PCI of any lesion. Planned Revascularization: Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated. Unplanned Revascularization: Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
Any ischemia driven de novo revascularization
Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Any ischemia driven de novo revascularization
Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Any ischemia driven de novo revascularization
Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Ischemia driven target vessel revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Ischemia driven target vessel revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Ischemia driven target vessel revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Ischemia driven treated target lesion revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Ischemia driven treated target lesion revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Ischemia driven treated target lesion revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Ischemia driven, measured segment revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Ischemia driven, measured segment revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR (both treated and not treated). In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Ischemia driven, measured segment revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Ischemia driven measured segment de novo revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Ischemia driven measured segment de novo revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Ischemia driven measured segment de novo revascularization
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Feasibility of QFR
Percentage of successful QFR in patients allocated to a QFR based diagnostic strategy
Feasibility of FFR
Percentage of successfully performed FFR measurements in vessels with attempted FFR (vessel level) Percentages of patients with successful FFR measurements (all attempted)
Number of lesion interrogated
Total number of lesions diagnosed with either QFR or FFR during the procedure
Procedure time
Time from introduction of the sheet until the sheet for coronary access is removed from the patient
Contrast volume
Total volume of contrast used in the procedure
Fluoroscopy time
Total fluoroscopy time for the procedure
Number of stents implanted
Total number of stents implanted during the procedure. Stents implanted in a staged procedure are included

Full Information

First Posted
November 1, 2018
Last Updated
July 25, 2023
Sponsor
Aarhus University Hospital Skejby
Collaborators
Medis Medical Imaging Systems
search

1. Study Identification

Unique Protocol Identification Number
NCT03729739
Brief Title
Functional Assessment by Virtual Online Reconstruction. The FAVOR III Europe Japan Study
Acronym
FAVOR III EJ
Official Title
Comparison of Quantitative Flow Ratio (QFR) and Conventional Pressure-wire Based Functional Evaluation for Guiding Coronary Intervention. A Randomized Clinical Non-inferiority Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 6, 2018 (Actual)
Primary Completion Date
July 21, 2023 (Actual)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aarhus University Hospital Skejby
Collaborators
Medis Medical Imaging Systems

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. QFR is estimated based on two angiographic projections. Studies have shown a good correlation with the present wire-based standard approach Fractional Flow Reserve (FFR) for assessment of intermediate coronary stenosis. The purpose of the FAVOR III Europe Japan study is to investigate if a QFR-based diagnostic strategy will results in non-inferior clinical outcome after 12 months compared to a standard pressure-wire guided strategy in evaluation of patients with chest pain (stable angina pectoris) and intermediate coronary stenosis.
Detailed Description
Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by visual assessment of the angiogram, but physiological assessment of the functional significance by fractional flow reserve has been shown to improve clinical outcome, to reduce number of stents implanted, and has obtained the highest recommendation in European guidelines. FFR is assessed during CAG by advancing a wire with a pressure transducer towards the stenosis and measure the ratio in pressure between the two sides of the stenosis during medical induced maximum blood flow (hyperaemia). The solid evidence for FFR evaluation of coronary stenosis and the relative simplicity in performing the measurements have supported adoption of an FFR based strategy but the need for interrogating the stenosis by a pressure wire, the small risks associated hereto, the cost of the wire, and the drug inducing hyperaemia has limited more widespread adoption. Quantitative Flow Ratio is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on computation of two angiographic projections. Two multi-center studies, the FAVOR II Europe-Japan and China studies evaluated the feasibility and diagnostic performance of in-procedure QFR, showing very good agreement between QFR and FFR. The purpose of the FAVOR III Europe Japan study is to investigate if a QFR-based diagnostic strategy yields non-inferior 12-month clinical outcome compared to a standard pressure-wire guided strategy in evaluation of patients with stable angina pectoris and intermediate coronary stenosis. Primary hypothesis: A QFR based diagnostic strategy results in non-inferior clinical outcome, assessed by a composite endpoint of all cause death, non-fatal myocardial infarction (MI) and unplanned revascularization after one year, compared to a strategy of pressure wire-based FFR for assessment of physiological significance of intermediate coronary artery stenosis. Methods: Investigator initiated, 1:1 randomized, prospective, clinical outcome, non-inferiority, multi-center trial performed at up to 40 international sites with inclusion of 2000 patients. Patients with stable angina pectoris or need for evaluation of non-culprit lesions after acute MI are enrolled. At least two angiographic projections are acquired during resting conditions. If the angiographic criteria are met, the patient is randomized to either a QFR- or an FFR-based diagnostic strategy. Revascularization is performed according to best standard by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Patient follow-up is continued until 24 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Fractional Flow Reserve (FFR), Quantitative Flow Ratio (QFR), Stable coronary artery disease, Angina pectoris, Angiography derived fractional flow reserve

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized clinical non-inferiority trial
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
2001 (Actual)

8. Arms, Groups, and Interventions

Arm Title
QFR-based diagnostic strategy
Arm Type
Experimental
Arm Description
Intermediate stenosis with indication for evaluation are diagnosed by Quantitative flow ratio (QFR). Revascularization is indicated if QFR≤0.80. Treatment is performed according to standard clinical practice.
Arm Title
FFR-based diagnostic strategy
Arm Type
Active Comparator
Arm Description
Intermediate stenosis with indication for evaluation are diagnosed by fractional flow reserve (FFR). Revascularization is indicated if FFR≤0.80. Treatment is performed according to standard clinical practice.
Intervention Type
Diagnostic Test
Intervention Name(s)
QFR-based diagnostic strategy
Intervention Description
Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
Intervention Type
Diagnostic Test
Intervention Name(s)
FFR-based diagnostic strategy
Intervention Description
Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
Primary Outcome Measure Information:
Title
Patient oriented composite endpoint (PoCE)
Description
A composite endpoint of 1) all-cause mortality, 2) any myocardial infarction, and 3) any unplanned revascularization
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Target vessel failure
Description
A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization.
Time Frame
1 month
Title
Target vessel failure
Description
A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization.
Time Frame
12 months
Title
Target vessel failure
Description
A composite of cardiac death, target vessel myocardial infarction and ischemic driven target vessel revascularization.
Time Frame
24 months
Title
All-cause mortality
Description
Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons.
Time Frame
1 month
Title
All-cause mortality
Description
Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons.
Time Frame
12 months
Title
All-cause mortality
Description
Total death includes cardiac death and other fatal categories such as cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurism will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons.
Time Frame
24 months
Title
Cardiac death
Description
Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death
Time Frame
1 month
Title
Cardiac death
Description
Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death
Time Frame
12 months
Title
Cardiac death
Description
Encompasses death due to coronary heart disease including fatal myocardial infarction, sudden cardiac death including fatal arrhythmias and cardiac arrest without successful resuscitation, death from heart failure including cardiogenic shock, and death related the cardiac procedure within 28 days from the procedure. If death is not clearly attributable to other non-cardiac causes it is adjudicated as cardiac death
Time Frame
24 months
Title
Myocardial infarction
Description
Procedure and non-procedure related myocardial infarction. Protocol defined.
Time Frame
1 month
Title
Myocardial infarction
Description
Procedure and non-procedure related myocardial infarction. Protocol defined.
Time Frame
12 months
Title
Myocardial infarction
Description
Procedure and non-procedure related myocardial infarction. Protocol defined.
Time Frame
24 months
Title
Target vessel myocardial infarction
Description
As "any myocardial infarction", but with culprit lesion in index vessel.
Time Frame
1 month
Title
Target vessel myocardial infarction
Description
As "any myocardial infarction", but with culprit lesion in index vessel.
Time Frame
12 months
Title
Target vessel myocardial infarction
Description
As "any myocardial infarction", but with culprit lesion in index vessel.
Time Frame
24 months
Title
Any unplanned revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of any lesion. Planned Revascularization: Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated. Unplanned Revascularization: Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
Time Frame
1 month
Title
Any unplanned revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of any lesion. Planned Revascularization: Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated. Unplanned Revascularization: Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
Time Frame
12 months
Title
Any unplanned revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of any lesion. Planned Revascularization: Revascularization is considered planned when it is decided at the time of the index procedure, based on the results of angiography and functional testing. Planned revascularization could be performed at the time of the index procedure or within 60 days. Such revascularization is considered as "primary" revascularization and is not considered as an endpoint. The "planned" status of the revascularization is adjudicated. Unplanned Revascularization: Revascularization is considered "unplanned" when not performed as part of standard care during the index procedure or if it is not planned as a staged procedure to occur within 60 days.
Time Frame
24 months
Title
Any ischemia driven de novo revascularization
Description
Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
1 month
Title
Any ischemia driven de novo revascularization
Description
Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
12 months
Title
Any ischemia driven de novo revascularization
Description
Coronary artery bypass grafting or PCI of a vessel that was not evaluated nor treated during the index procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
24 months
Title
Ischemia driven target vessel revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
1 month
Title
Ischemia driven target vessel revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
12 months
Title
Ischemia driven target vessel revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
24 months
Title
Ischemia driven treated target lesion revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
1 month
Title
Ischemia driven treated target lesion revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
12 months
Title
Ischemia driven treated target lesion revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel with documented ischemia that was treated during index or planned staged procedure. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI
Time Frame
24 months
Title
Ischemia driven, measured segment revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Time Frame
1 month
Title
Ischemia driven, measured segment revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR (both treated and not treated). In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Time Frame
12 months
Title
Ischemia driven, measured segment revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Time Frame
24 months
Title
Ischemia driven measured segment de novo revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Time Frame
1 month
Title
Ischemia driven measured segment de novo revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Time Frame
12 months
Title
Ischemia driven measured segment de novo revascularization
Description
Coronary artery bypass grafting (CABG) or PCI of a study vessel that was evaluated by either FFR or QFR but not treated. In stable patients, ischemia should always be documented, using for example FFR, SPECT scan or MRI.
Time Frame
24 months
Title
Feasibility of QFR
Description
Percentage of successful QFR in patients allocated to a QFR based diagnostic strategy
Time Frame
1 hour
Title
Feasibility of FFR
Description
Percentage of successfully performed FFR measurements in vessels with attempted FFR (vessel level) Percentages of patients with successful FFR measurements (all attempted)
Time Frame
1 hour
Title
Number of lesion interrogated
Description
Total number of lesions diagnosed with either QFR or FFR during the procedure
Time Frame
1 hour
Title
Procedure time
Description
Time from introduction of the sheet until the sheet for coronary access is removed from the patient
Time Frame
1 hour
Title
Contrast volume
Description
Total volume of contrast used in the procedure
Time Frame
1 hour
Title
Fluoroscopy time
Description
Total fluoroscopy time for the procedure
Time Frame
1 hour
Title
Number of stents implanted
Description
Total number of stents implanted during the procedure. Stents implanted in a staged procedure are included
Time Frame
1 hour

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of 18 years and above Both genders Indication for invasive coronary angiography Patients with stable angina pectoris, or assessment of secondary lesions in stabilized non-STEMI patients or assessment of secondary lesions in patients with prior STEMI and staged evaluation of secondary lesions. Able to provide written informed consent Angiographic inclusion criteria Diameter stenosis of 40-90% diameter stenosis Vessel diameter of at least 2.5 mm and supplying viable myocardium Patients with restenosis in a native coronary artery can be included Exclusion Criteria: Severely impaired renal function: Glomerular filtration rate (GFR) < 20 mL/min/1.73m² Life expectancy less than one year Cardiogenic shock or unstable haemodynamic state (Killip class III and IV) ST-elevation myocardial infarction (STEMI) within 72 hours Bypass graft to any target vessel Atrial fibrillation at the time of the procedure Chronic total occlusions of any vessel with possible or established indication for treatment Pregnancy or intention to become pregnant during the course of the trial Breast feeding Planned need for concomitant valvular or aortic surgery Left ventricular ejection fraction (LVEF) < 30% Previous inclusion in the FAVOR III trial Enrolled in another clinical study, and for this reason not treated according to present European Society of Cardiology guidelines, or the protocol treatment conflicts with the protocol treatment of FAVOR III Inability to tolerate contrast media Inability to tolerate Adenosine Angiographic exclusion criteria Ostial right coronary artery > 50% diameter stenosis Left main coronary artery > 50% diameter stenosis Lesions properties indicative of myocardial bridging Bifurcation lesions with major (>1 mm) step down in reference size across the bifurcation Severe tortuosity of any target vessel Severe overlap in the stenosed segment Poor image quality precluding identification of vessel contours
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Evald H. Christiansen, Prof.
Organizational Affiliation
Aarhus University Hospital, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aalborg University Hospital
City
Aalborg
ZIP/Postal Code
9100
Country
Denmark
Facility Name
Aarhus University Hospital
City
Aarhus N
ZIP/Postal Code
8000
Country
Denmark
Facility Name
Gentofte Hospital
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
Facility Name
Institut Arnault Tzanck
City
Saint-Laurent-du-Var
State/Province
Nice
ZIP/Postal Code
06700
Country
France
Facility Name
GCS ES Axium - Parc Rambot
City
Aix-en-Provence
ZIP/Postal Code
13097
Country
France
Facility Name
CHU de Lille, Lille University Hospital
City
Lille
ZIP/Postal Code
59000
Country
France
Facility Name
Institut Cardiovasculaire Paris Sud (ICPS), Hopital Jacques Cartier
City
Massy
ZIP/Postal Code
91300
Country
France
Facility Name
Hopital Haut-Leveque, Pessac
City
Pessac
ZIP/Postal Code
33600
Country
France
Facility Name
Hôpital Privé Claude Galien
City
Quincy
ZIP/Postal Code
91480
Country
France
Facility Name
Clinique Pasteur, Toulouse
City
Toulouse
ZIP/Postal Code
31076
Country
France
Facility Name
Charite-Universitatsmedizin Berlin
City
Berlin
ZIP/Postal Code
12200
Country
Germany
Facility Name
Elisabeth Krankenhaus
City
Essen
ZIP/Postal Code
45138
Country
Germany
Facility Name
University Clinic Leipzig
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
Ospedale Maggiore, AUSL Bologna
City
Bologna
ZIP/Postal Code
40133
Country
Italy
Facility Name
Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara
City
Ferrara
ZIP/Postal Code
44124
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria Federico II di Napoli
City
Naples
ZIP/Postal Code
80138
Country
Italy
Facility Name
San Luigi Gonzaga University Hospital, Turin
City
Orbassano
ZIP/Postal Code
10043
Country
Italy
Facility Name
Arcispedale S. Maria Nuova di Reggio Emilia
City
Reggio Emilia
ZIP/Postal Code
42123
Country
Italy
Facility Name
Ospedale degli Infermi di Rimini
City
Rimini
ZIP/Postal Code
47923
Country
Italy
Facility Name
Ospedale di Rivoli, Torino
City
Torino
ZIP/Postal Code
10098
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria integrata Verona
City
Verona
ZIP/Postal Code
37126
Country
Italy
Facility Name
Riga Stradini University Hospital
City
Riga
ZIP/Postal Code
1002
Country
Latvia
Facility Name
Hospital of Lithuanian University of Health Sciences Kauno Klinikos
City
Kaunas
ZIP/Postal Code
50161
Country
Lithuania
Facility Name
VU University Medical Center
City
Amsterdam
ZIP/Postal Code
1081
Country
Netherlands
Facility Name
Academic Medical Center (AMC)
City
Amsterdam
ZIP/Postal Code
1105
Country
Netherlands
Facility Name
HagaZiekenhuis
City
The Hague
ZIP/Postal Code
2545
Country
Netherlands
Facility Name
Medical University of Warsaw
City
Warsaw
ZIP/Postal Code
PL 02-097
Country
Poland
Facility Name
Hospital Clinico Universitario Virgen de la Arrixaca
City
El Palmar
State/Province
Murcia
ZIP/Postal Code
30120
Country
Spain
Facility Name
Hospital Clinico de Coruña
City
Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Hospital Lucus Agusti LUGO
City
Lugo
ZIP/Postal Code
27003
Country
Spain
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Clinico Universitario de Valladolid
City
Valladolid
ZIP/Postal Code
47003
Country
Spain
Facility Name
Hospital Álvaro Cunqueiro
City
Vigo
ZIP/Postal Code
36312
Country
Spain
Facility Name
Sahlgrenska University Hospital
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden
Facility Name
Barbera Stähli
City
Zürich
State/Province
Zûrich
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
27712739
Citation
Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JHC, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013.
Results Reference
background
PubMed Identifier
29980523
Citation
Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, Liu T, Di Serafino L, Di Girolamo D, Escaned J, Nef H, Naber C, Barbierato M, Tu S, Neghabat O, Madsen M, Tebaldi M, Tanigaki T, Kochman J, Somi S, Esposito G, Mercone G, Mejia-Renteria H, Ronco F, Botker HE, Wijns W, Christiansen EH, Holm NR. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. J Am Heart Assoc. 2018 Jul 6;7(14):e009603. doi: 10.1161/JAHA.118.009603.
Results Reference
background
PubMed Identifier
29555835
Citation
Westra J, Tu S, Winther S, Nissen L, Vestergaard MB, Andersen BK, Holck EN, Fox Maule C, Johansen JK, Andreasen LN, Simonsen JK, Zhang Y, Kristensen SD, Maeng M, Kaltoft A, Terkelsen CJ, Krusell LR, Jakobsen L, Reiber JHC, Lassen JF, Bottcher M, Botker HE, Christiansen EH, Holm NR. Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study (Wire-Free Functional Imaging II). Circ Cardiovasc Imaging. 2018 Mar;11(3):e007107. doi: 10.1161/CIRCIMAGING.117.007107.
Results Reference
background
PubMed Identifier
29101020
Citation
Xu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, Guo L, Sun Z, Li Z, Tian F, Fang W, Chen J, Li W, Guan C, Holm NR, Wijns W, Hu S. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. J Am Coll Cardiol. 2017 Dec 26;70(25):3077-3087. doi: 10.1016/j.jacc.2017.10.035. Epub 2017 Oct 31.
Results Reference
background

Learn more about this trial

Functional Assessment by Virtual Online Reconstruction. The FAVOR III Europe Japan Study

We'll reach out to this number within 24 hrs